

15<sup>th</sup> World Congress on

Biotechnology And Biotech Industries Meet  
&

2<sup>nd</sup> International Conference on

Enzymology and Molecular Biology

March 20-21, 2017 Rome, Italy

---

### Novel human indoleamine 2,3-dioxygenase inhibitors form a long-lived complex with the enzyme

Julie Alexandre, Michael Swan, Mike Latchem, Dean Boyall, John Pollard, Stuart Hughes and James Westcott  
Vertex Pharmaceuticals Ltd., UK

**H**uman indoleamine 2,3-dioxygenase 1 (IDO) catalyzes the conversion of L-tryptophan (L-Trp) to N-formylkynurenine through a heme and  $\alpha$ -ketoglutarate dependent oxidation process. IDO is recognized as a central regulator of immune responses in a broad variety of physiological and pathological settings and is thus considered an attractive therapeutic target. In search of novel IDO inhibitors, we

Notes: